NBIX
Companies
NASDAQ
Neurocrine Biosciences Inc.
Health Care
$127.31
-$9.19 (-6.73%)
Price Chart
Overview
About NBIX
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Market Cap
$13.6B
Volume
258.9M
Avg. Volume
236.9M
P/E Ratio
19.487923
Dividend Yield
0.00%
Employees
1.3K
Company Information
Exchange
NASDAQ
Sector
Health Care
Industry
Drug Manufacturers - Specialty & Generic
Website
Risk & Correlation Analysis
Market Correlation
0.60
Low Correlation
Volatility
Medium (0.39)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, NBIX shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$13.6B
Volume258.9M
P/E Ratio19.49
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 6, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025